Renvela: new phosphate binder formulation

Renvela is available in the same 800mg tablet presentation as Renagel, as well as 2.4g sachets of powder for oral suspension.
Renvela is available in the same 800mg tablet presentation as Renagel, as well as 2.4g sachets of powder for oral suspension.

Genzyme has launched Renvela, a new version of the phosphate binder sevelamer.

Sevelamer is a crosslinked polymer that binds phosphate molecules in the intestine.

Renvela contains the carbonate salt of the drug, whereas the existing formulation Renagel contains sevelamer hydrochloride.

Both are licensed for the treatment of hyperphosphataemia in patients on dialysis. Renvela is also licensed for use in patients with chronic kidney disease not on dialysis.

Two randomised controlled trials in the haemodialysis setting (one in 79 patients, the other in 31 patients) demonstrated the equivalence of sevelamer carbonate tablets and powder, respectively, to sevelamer hydrochloride tablets for serum phosphate control.

View Renvela drug record

Further information: Genzyme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.

Researchers query safety of delaying antibiotics for UTI in elderly

Researchers query safety of delaying antibiotics for UTI in elderly

Delaying or withholding antibiotics for symptoms of...